Astellas Pharma Inc.
ALPMF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $31,237,000 | $17,045,000 | $132,361,000 | $156,886,000 |
| Dep. & Amort. | $199,132,000 | $157,840,000 | $105,738,000 | $79,684,000 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $0 | $0 | $0 |
| Change in WC | -$166,369,000 | -$86,518,000 | -$24,209,000 | $5,956,000 |
| Other Non-Cash | $130,512,000 | $84,108,000 | $113,877,000 | $14,918,000 |
| Operating Cash Flow | $194,512,000 | $172,475,000 | $327,767,000 | $257,444,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$37,003,000 | -$38,056,000 | -$88,541,000 | -$76,448,000 |
| Net Acquisitions | $0 | -$784,974,000 | $0 | -$670,000 |
| Inv. Purchases | $0 | $0 | $0 | -$5,576,000 |
| Inv. Sales/Matur. | $12,920,000 | $0 | $12,624,000 | $5,576,000 |
| Other Inv. Act. | -$65,336,000 | -$22,772,000 | -$8,583,000 | $14,705,000 |
| Investing Cash Flow | -$89,419,000 | -$845,802,000 | -$84,500,000 | -$62,413,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$88,522,000 | $771,233,000 | -$15,000,000 | -$60,000,000 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$6,960,000 | -$10,735,000 | -$60,556,000 | -$50,717,000 |
| Dividends Paid | -$128,993,000 | -$116,653,000 | -$100,355,000 | -$85,236,000 |
| Other Fin. Act. | -$36,892,000 | -$29,785,000 | -$19,712,000 | -$20,345,000 |
| Financing Cash Flow | -$261,367,000 | $614,060,000 | -$195,623,000 | -$216,298,000 |
| Forex Effect | $8,960,000 | $18,113,000 | $13,210,000 | $11,125,000 |
| Net Chg. in Cash | -$147,315,000 | -$41,153,000 | $60,854,000 | -$10,142,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $335,687,000 | $376,840,000 | $315,986,000 | $326,128,000 |
| End Cash | $188,372,000 | $335,687,000 | $376,840,000 | $315,986,000 |
| Free Cash Flow | $137,182,000 | $89,978,000 | $239,226,000 | $180,996,000 |